Trials / Unknown
UnknownNCT02854618
Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
Study of the Immune Response T Anti-tumoral Cluster of Differentiation 4 (CD4) for Patients Treated for a Metastatic Breast Cancer by Everolimus Within the Framework of Its Marketing Authorization
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 112 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- Female
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the immune response for patients affected by metastatic breast cancer treated by everolimus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | additional blood sample |
Timeline
- Start date
- 2015-11-26
- Primary completion
- 2022-05-01
- Completion
- 2022-05-01
- First posted
- 2016-08-03
- Last updated
- 2021-02-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02854618. Inclusion in this directory is not an endorsement.